Studying the COVID-19 Vaccine For Children
In the fight against COVID-19, a vaccine is a critical part of addressing the global health crisis by decreasing rates of infection, disease and death worldwide. The landmark Pfizer-BioNTech Phase 3 clinical trial began in late July 2020, recruiting
participants aged 12 and over. Close to three thousand participants were adolescents:
2,259 participants were between the ages of 12-15 and 754 participants were 16 and 17 years old. In March 2021, Pfizer and BioNTech dosed the first healthy children in a global Phase 1/2/3 continuous study to learn if the vaccine can produce an immune response against COVID-19, and if it is safe, in children aged 6 months to 11 years.
Pfizer:
https://www.pfizer.com/science/clinical-trials/children